急性缺血性卒中可见颅内闭塞患者再通与临床、影像及血栓特征的相关性
这项多中心前瞻性队列研究纳入12个中心575例CT血管造影(CTA)证实颅内动脉闭塞的急性缺血性卒中患者,其中47.8%仅接受静脉阿替普酶、33.9%接受静脉阿替普酶加血管内取栓、8.3%仅取栓、9.9%保守治疗。基线CTA至再通评估中位时间158分钟,总体成功再通率27.3%(157/575),接受阿替普酶者30.4%(143/470) vs 未接受者13.3%(14/105),差值17.1%(95%CI 10.2%-25.8%)。接受阿替普酶患者中,治疗开始至再通评估时间每增加30分钟与再通相关(OR 1.28,95%CI 1.18-1.38),远端M1大脑中动脉再通率46.4%(39/84) vs 颈内动脉10.9%(10/92)(OR 5.61,95%CI 2.38-13.26),发丝状残余血流66.7%(30/45) vs 无残余血流24.1%(91/377)(OR 7.03,95%CI 3.32-14.87)。作者认为这些发现可能有助于急性缺血性卒中患者的治疗和分诊决策。
要点
- 接受静脉阿替普酶者成功再通率30.4%(143/470),未接受者13.3%(14/105),差值17.1%(95%CI 10.2%-25.8%)。
- 接受阿替普酶患者中,治疗开始至再通评估时间每增加30分钟,再通OR 1.28(95%CI 1.18-1.38)。
- 远端M1大脑中动脉闭塞再通率46.4%(39/84) vs 颈内动脉10.9%(10/92),OR 5.61(95%CI 2.38-13.26)。
- 血栓通透性为发丝状残余血流者再通率66.7%(30/45) vs 无残余血流24.1%(91/377),OR 7.03(95%CI 3.32-14.87)。
- 未接受阿替普酶患者动脉再通率低,总体成功再通率27.3%(157/575)。
适用人群与场景
- 12个中心(加拿大、西班牙、韩国、捷克共和国、土耳其)575例急性缺血性卒中且CTA证实颅内动脉闭塞的患者,中位年龄72岁(IQR 63-80),51.5%为男性。
- 纳入场景为CTA证实颅内动脉闭塞后6小时内重复CTA或首次血管造影评估再通。
诊断标准与关键阈值
- 颅内动脉闭塞由CT血管造影(CTA)证实。
- 再通定义采用修订版动脉闭塞量表(rAOL),评分0分(原闭塞病变不变)至3分(原闭塞完全血运重建),在基线CTA后6小时内重复CTA或受影响颅内循环首次血管造影采集时评估。
处置流程与药物剂量
- 275例(47.8%)仅接受静脉阿替普酶治疗。
- 195例(33.9%)接受静脉阿替普酶加血管内取栓治疗。
- 48例(8.3%)仅接受血管内取栓治疗。
- 57例(9.9%)接受保守治疗。
研究设计与关键结果
- 多中心前瞻性队列研究,575例CTA证实颅内动脉闭塞的急性缺血性卒中患者,来自12个中心。
- 总体成功再通率27.3%(157/575);接受静脉阿替普酶者30.4%(143/470) vs 未接受者13.3%(14/105),差值17.1%(95%CI 10.2%-25.8%)。
- 基线CTA至再通评估中位时间158分钟(IQR 79-268);静脉阿替普酶开始至再通评估中位时间132.5分钟(IQR 62-238)。
- 接受阿替普酶患者中,治疗开始至再通评估时间每增加30分钟与再通相关(OR 1.28,95%CI 1.18-1.38)。
- 接受阿替普酶患者中,远端M1大脑中动脉闭塞再通率46.4%(39/84) vs 颈内动脉10.9%(10/92),OR 5.61(95%CI 2.38-13.26)。
- 接受阿替普酶患者中,发丝状残余血流(血栓通透性)再通率66.7%(30/45) vs 无残余血流24.1%(91/377),OR 7.03(95%CI 3.32-14.87)。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,急性缺血性卒中患者中,血栓位置越远端、血栓通透性越高、再通评估时间越长,与静脉阿替普酶后动脉再通相关;未接受阿替普酶者动脉再通率低,这些发现可能有助于治疗和分诊决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Recanalization of intracranial thrombus is associated with improved clinical outcome in patients with acute ischemic stroke. The association of intravenous alteplase treatment and thrombus characteristics with recanalization over time is important for stroke triage and future trial design.
OBJECTIVE: To examine recanalization over time across a range of intracranial thrombus occlusion sites and clinical and imaging characteristics in patients with ischemic stroke treated with intravenous alteplase or not treated with alteplase.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter prospective cohort study of 575 patients from 12 centers (in Canada, Spain, South Korea, the Czech Republic, and Turkey) with acute ischemic stroke and intracranial arterial occlusion demonstrated on computed tomographic angiography (CTA).
EXPOSURES: Demographics, clinical characteristics, time from alteplase to recanalization, and intracranial thrombus characteristics (location and permeability) defined on CTA.
MAIN OUTCOMES AND MEASURES: Recanalization on repeat CTA or on first angiographic acquisition of affected intracranial circulation obtained within 6 hours of baseline CTA, defined using the revised arterial occlusion scale (rAOL) (scores from 0 [primary occlusive lesion remains the same] to 3 [complete revascularization of primary occlusion]).
RESULTS: Among 575 patients (median age, 72 years [IQR, 63-80]; 51.5% men; median time from patient last known well to baseline CTA of 114 minutes [IQR, 74-180]), 275 patients (47.8%) received intravenous alteplase only, 195 (33.9%) received intravenous alteplase plus endovascular thrombectomy, 48 (8.3%) received endovascular thrombectomy alone, and 57 (9.9%) received conservative treatment. Median time from baseline CTA to recanalization assessment was 158 minutes (IQR, 79-268); median time from intravenous alteplase start to recanalization assessment was 132.5 minutes (IQR, 62-238). Successful recanalization occurred at an unadjusted rate of 27.3% (157/575) overall, including in 30.4% (143/470) of patients who received intravenous alteplase and 13.3% (14/105) who did not (difference, 17.1% [95% CI, 10.2%-25.8%]). Among patients receiving alteplase, the following factors were associated with recanalization: time from treatment start to recanalization assessment (OR, 1.28 for every 30-minute increase in time [95% CI, 1.18-1.38]), more distal thrombus location, eg, distal M1 middle cerebral artery (39/84 [46.4%]) vs internal carotid artery (10/92 [10.9%]) (OR, 5.61 [95% CI, 2.38-13.26]), and higher residual flow (thrombus permeability) grade, eg, hairline streak (30/45 [66.7%]) vs none (91/377 [24.1%]) (OR, 7.03 [95% CI, 3.32-14.87]).
CONCLUSIONS AND RELEVANCE: In patients with acute ischemic stroke, more distal thrombus location, greater thrombus permeability, and longer time to recanalization assessment were associated with recanalization of arterial occlusion after administration of intravenous alteplase; among patients who did not receive alteplase, rates of arterial recanalization were low. These findings may help inform treatment and triage decisions in patients with acute ischemic stroke.
参考来源
- Menon BK, Al-Ajlan FS, Najm M, et al. Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke. JAMA. 2018. PMID: 30208455. doi:10.1001/jama.2018.12498
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。